Washington, DC – May 7, 2024 – A new publication by Friends of Cancer Research (Friends) was recently published in the journal Diagnostics: “Advancing Evidence Generation for ctDNA: Lessons Learned from A Multi-Assay Study of Baseline ctDNA Levels Across Cancer Types and Stages.” This collaborative publication evaluates circulating tumor DNA (ctDNA) levels prior to cancer…
A new publication by Friends of Cancer Research (Friends) was published in Cytotherapy, “Accelerated Development of Genetically Engineered Cellular Therapies: A Framework for Extrapolating Data Across Related Products.” This exciting manuscript examines the current opportunities and challenges with development approaches of genetically engineered cellular therapies to propose solutions to optimize development. The publication outlines a…
Friends of Cancer Research (Friends) is excited to announce the launch of a new research partnership, Digital and Computational Pathology Tool Harmonization (Digital PATH) Project. This project will identify factors that may contribute to variability in biomarker assessment across computational pathology platforms, propose areas for alignment in the field, and provide insights for shaping regulatory…
Friends of Cancer Research (Friends) is honored to announce the addition of Roy S. Herbst, MD, PhD, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital and Assistant Dean for Translational Research at Yale School of Medicine, to its Board of Directors. Dr. Herbst is a nationally recognized expert in lung cancer treatment and…
A new manuscript by Friends of Cancer Research (Friends) published today in AACR’s Clinical Cancer Research, shows that a substantial number of oncology drugs undergo additional dose evaluation after approval through Postmarketing Requirements (PMRs), studies that sponsors are required to conduct after approval to gather additional information about a product’s safety and/or efficacy. These findings…
Friends of Cancer Research (Friends) applauds President Biden for nominating Dr. W. Kimryn Rathmell as Director of the National Cancer Institute (NCI) and extends our deepest gratitude to recently confirmed Director of the National Institutes of Health, Dr. Monica Bertagnolli, for her steadfast leadership as Director of the NCI. “Dr. Rathmell brings extensive scientific expertise…
FDA Commissioner Califf to Receive the Ellen V. Sigal Advocacy Leadership Award Congresswoman Dingell to Receive the Marlene A. Malek Public Service Award Washington, DC – August 15, 2023 – Friends of Cancer Research (Friends) is proud to announce our 2023 Cancer Leadership Awards honorees: Commissioner of the U.S. Food and Drug Administration, Dr. Robert Califf,…
Friends of Cancer Research (Friends) is excited to present data from three current projects at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings are catalyzing meaningful improvements in oncology drug development and informing regulatory policy and patient care. Abstract Details Changes in ctDNA levels as an early indicator of outcomes in…
Friends of Cancer Research (Friends) thanks President Joe Biden for nominating Dr. Monica Bertagnolli as the Director of the National Institute of Health (NIH). “At this critical time for innovation at the NIH, Dr. Bertagnolli will be the visionary leader we need,” said Ellen Sigal, Chair & Founder of Friends of Cancer Research. As the…
Friends of Cancer Research (Friends) commends the National Cancer Institute (NCI) and their Director Dr. Monica Bertagnolli, for the recently announced National Cancer Plan. This critical and innovative plan provides a framework for collaboration and partnership across agencies seeking to improve the lives of millions of cancer patients and families. “Dr. Bertagnolli and the Biden…
